A Transformational Approach to Treating Alzheimer’s Disease … and more.
T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease, a drug with the potential to slow, stop or reverse the course of the disease.
T3D-959 has the potential to be a transformational therapy because it acts in a multi-faceted manner; the drug addresses and improves the most important defects of Alzheimer’s disease that cause the starvation and the strangulation.
This process starts with the likely ‘triggers’ for the disease, insulin resistance and IGF-resistance (insulin-like growth factor), which cause the poor metabolism of energy. These, in turn, cause DCGM (Diminished Cerebral Glucose Metabolism) which precedes neurodegeneration. Hence, the description of Alzheimer’s disease as a neuro-metabolic disorder.
T3D-959, therefore, has been shown in pre-clinical trials to be a disease-modifying drug. For humans, it is an orally-delivered, once-a-day medicine for Alzheimer’s disease’s patients with mild to moderate disease severity, and potentially patients with mild cognitive impairment (MCI). As one can surmise, the mechanism of action of the new drug, T3D-959, may also provide therapeutic benefit in other central nervous system (CNS) or neurodegenerative disorders.